Form 4 Filing for Aclaris Therapeutics, Inc. - Insider Transactions

This filing details transactions by Mehra Anand, a director at Aclaris Therapeutics, Inc. On June 4, 2026, Anand acquired 42,350 Stock Options and 10,987 Restricted Stock Units (RSUs). The stock options have an exercise price of $4.71 and vest in monthly installments starting July 4, 2026. The RSUs vest on June 4, 2027. On June 5, 2026, 11,580 RSUs vested, and Anand also acquired 11,580 shares of Common Stock. Following these transactions, Anand holds 726,403 shares of Common Stock directly. The RSUs represent a contingent right to receive one share of common stock upon vesting.